[Federal Register Volume 64, Number 137 (Monday, July 19, 1999)]
[Notices]
[Page 38685]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-18376]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Glycoprotein Hormone
Superagonists
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
U.S. Patent Application Serial No. 09/185,408 filed May 6, 1996
entitled ``Glycoprotein Hormone Superagonists'', to University of
Maryland, having a place of business in Baltimore, Maryland. The United
States of America is the assignee of the patent rights in this
invention.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before
September 17, 1999 will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Charles Maynard, Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 496-7056, ext. 243; Facsimile: (301) 402-0220; e-mail:
[email protected]
SUPPLEMENTARY INFORMATION: This invention relates generally to modified
glycoprotein hormones and specifically to modifications to a human
glycoprotein, which create superagonist activity. Glycoprotein hormones
comprise a family of hormones, which are structurally related
heterodimers consisting of a species common sub-unit and a
distinct sub-unit that confers the biological activity for
each hormone. However, this invention is not limited to specific
hormones, specific subjects such as humans as well as non-humans
mammals, specific amino acids, specific clinical conditions, specific
analogs, or specific methods.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 12, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 99-18376 Filed 7-16-99; 8:45 am]
BILLING CODE 4140-01-M
